Goethe University Frankfurt
Verified site
Frankfurt, Germany
Rare diseases
Investigational molecules
Locations
A plain-language summary of the goals, design and what participants do
The study focuses on Metastatic Castration-resistant Prostate Cancer, a form of prostate cancer that has spread to other parts of the body and continues to grow even when testosterone levels are low. The investigational therapy is a B7-H3 Antibody Drug Conjugate called risvutatug rezetecan, which is given by an intravenous infusion and is designed to carry a chemotherapy payload directly to cancer cells. Participants may also receive standard oral medicines such as enzalutamide or abiraterone acetate, which are commonly used to block hormone signals that fuel prostate cancer, and they may have previously been treated with a class of chemotherapy drugs known as Taxane and with ARPI (drugs that block the androgen receptor pathway).
The purpose of the study is to compare the effectiveness of risvutatug rezetecan with best supportive care, with or without continued hormone‑blocking therapy, in men whose disease has returned after earlier treatments.
Participants are randomly assigned to receive either the new intravenous medication or the standard oral regimen plus supportive care. Treatment is given over several cycles, with regular clinic visits for safety checks, blood tests, and imaging scans to monitor disease status. After the treatment period, participants continue to be followed for additional months to assess long‑term outcomes and any side effects.
The trial runs in 11 steps – from screening to follow-up. Each step says what happens and what the team monitors.
5 criteria
9 criteria
Tell us about your condition – we search every trial in Europe and connect you with the right site.
We usually reply within a few days
All sites with verified contact details – recruitment status may not be available; ask directly
Frankfurt, Germany
Utrecht, The Netherlands
Berlin, Germany
Where you can join this trial
Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.
Not yet recruitingJoining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.
Xtandi is a tablet taken by mouth that contains the medicine enzalutamide. It works by blocking the action of male hormones that can help prostate cancer grow. In this study it is used as a standard treatment to compare against the new drug.
GSK5764227 is an experimental medication that is given through an IV infusion. It is a type of antibody‑drug conjugate that targets a protein called B7‑H3 on cancer cells. The trial is testing whether this new therapy can slow or shrink the cancer in men whose disease has returned after other treatments.
ZYTIGA is a tablet taken by mouth that contains abiraterone acetate. It works by lowering the production of male hormones that can stimulate prostate cancer. In the trial it serves as another standard treatment used for comparison with the experimental drug.
Best supportive care (BSC) refers to routine medical care that helps manage symptoms and maintain quality of life. In this study participants may receive BSC alone or together with other hormone‑targeting drugs, providing a baseline against which the new therapy is measured.
This medication is taken as a film‑coated tablet taken by mouth. It is an approved drug widely used in the treatment of advanced prostate cancer and is well documented in medical literature. It works by blocking androgen receptors, preventing male hormones from stimulating cancer cells. It belongs to the class of anti‑androgen agents.
This investigational drug is supplied as a powder that is mixed for intravenous infusion. It is currently an experimental therapy under study and has not yet received market approval. It targets the B7‑H3 protein on cancer cells, delivering a toxic payload that kills the cells while sparing normal tissue. It is classified as an antibody‑drug conjugate (ADC).
This medication comes as a film‑coated tablet taken orally. It is an approved treatment for metastatic castration‑resistant prostate cancer and is well described in the literature. It blocks an enzyme needed to make testosterone, lowering hormone levels that fuel tumor growth. It is classified as a steroidal CYP17 inhibitor.
sourced from the EU Clinical Trials Register and site verification
Want to learn more about this trial or check if you can participate?
Tell us about your condition – we search every trial in Europe and connect you with the right site.